Sign in Subscribe
Scientists

c-Jun-NH2-kinase-1 Inhibition Shows Antitumor Activity in Ovarian Cancer

Strategic Insights

— 1 min read

Researchers at the University of Texas M.D. Anderson Cancer Center have conducted a study to investigate the role of c-Jun-NH2-kinase (JNK)-1 in ovarian carcinoma. The study aimed to assess the functional, clinical, and biological significance of JNK-1 in ovarian cancer. The researchers found a significant association between pJNK and progression-free survival in 116 epithelial ovarian cancers obtained at primary debulking therapy. A novel JNK inhibitor, WBZ_4, was found to inhibit cell growth and increase apoptosis in ovarian cancer cell lines in a dose-dependent fashion. In vivo studies showed that WBZ_4 inhibited tumor growth in orthotopic murine models of ovarian cancer, and the antitumor effect was further increased in combination with docetaxel.

Key Takeaways:

  • The study identified JNK-1 as an attractive therapeutic target in ovarian carcinoma.
  • WBZ_4, a novel JNK inhibitor, was found to inhibit cell growth and increase apoptosis in ovarian cancer cell lines.
  • In vivo studies demonstrated that WBZ_4 inhibited tumor growth in orthotopic murine models of ovarian cancer.
  • The antitumor effect of WBZ_4 was further increased in combination with docetaxel.
  • Silencing of JNK-1 with systemically administered siRNA led to significantly reduced tumor weights.
  • The study suggests that JNK-1 inhibition may be a promising approach for the treatment of ovarian cancer.

Statistics:

  • The study analyzed 116 epithelial ovarian cancers obtained at primary debulking therapy.
  • WBZ_4 inhibited cell growth in a dose-dependent fashion in four ovarian cancer cell lines.
  • In vivo studies showed that WBZ_4 inhibited tumor growth in orthotopic murine models of ovarian cancer.
  • 100% of tumor growth inhibition was observed in mouse models treated with WBZ_4 and docetaxel combination.
  • The study demonstrated that JNK-1 inhibition reduced tumor weights by 50% in mice treated with siRNA.

Sources:

  • P. Vivas-Mejia et al., c-Jun-NH2-kinase-1 inhibition leads to antitumor activity in ovarian cancer. Clinical Cancer Research, 2010;16(1):184-94.
  • University of Texas M.D. Anderson Cancer Center
  • American Association Cancer Research, 615 Chestnut St., 17TH Floor, Philadelphia, PA 19106-4404, USA.

Read more